Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma: A prospective flow cytometric study

Cancer

Volumn 82, Issue 1, 1998, Pages 49-59

  Lanza, Giovanni ^a   Gafà, Roberta ^a   Santini, Alessandra ^b   Maestri, Iva ^a   Dubini, Alessandra ^a   Gilli, Giuseppe ^b   Cavazzini, Luigi ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UO Pediatria e Adolescentologia   (Italy)

Author keywords

Colon carcinoma; DNA ploidy; Flow cytometry; Prognosis; Proximal and distal colon

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER SURVIVAL; COLON CARCINOMA; DNA CONTENT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PLOIDY; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; CARCINOMA; CELL NUCLEUS; COLONIC NEOPLASMS; CRYOPRESERVATION; DIPLOIDY; DISEASE-FREE SURVIVAL; DNA; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PLOIDIES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECTAL NEOPLASMS; REPRODUCIBILITY OF RESULTS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031893532     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980101)82:1<49::AID-CNCR6>3.0.CO;2-F     Document Type: Article

References (52)

1. Quirke P, Dixon MF, Clayden AD, Durdey P, Dyson JED, Williams NS, et al. Prognostic significance of DNA aneuploidy and cell proliferation in rectal adenocarcinomas. J Pathol 1987;151:285-91.
2. Schutte B, Reynders MMJ, Wiggers T, Arends JW, Volovics L, Bosman FT, et al. Retrospective analysis of the prognostic significance of DNA content and proliferative activity in large bowel carcinoma. Cancer Res 1987;47:5494-6.
3. Jones DJ, Moore M, Schofield PF. Refining the prognostic significance of DNA ploidy status in colorectal cancer: a prospective flow cytometric study. Int J Cancer 1988;41:206-10.
4. Jass JR, Mukawa K, Goh HS, Love SB, Capellaro D. Clinical importance of DNA content in rectal cancer measured by flow cytometry. J Clin Pathol 1989;42:254-9.
5. Halvorsen TB, Johannesen E. DNA ploidy, tumor site, and prognosis in colorectal cancer. A flow cytometric study of paraffin-embedded tissue. Scand J Gastroenterol 1990; 25:141-8.
6. Baretton G, Gille J, Oevermann E, Löhrs U. Flow-cytometric analysis of the DNA-content in paraffin-embedded tissue from colorectal carcinomas and its prognostic significance. Virchows Arch B Cell Pathol Inc Mol Pathol 1991;60:123-31.
7. Bosari S, Lee AKC, Wiley BD, Heatley GJ, Silverman ML. Flow cytometric and image analyses of colorectal adenocarcinomas: a comparative study with clinical correlations. Am J Clin Pathol 1993;99:187-94.
8. Chapman MAS, Hardcastle JD, Armitage NCM. Five-year prospective study of DNA tumor ploidy and colorectal cancer survival. Cancer 1995;76:383-7.
9. Scott NA, Wieand HS, Moertel CG, Cha SS, Beart RW, Lieber MM. Colorectal cancer: Dukes' stage, tumor site, preoperative plasma CEA level, and patient prognosis related to tumor DNA ploidy pattern. Arch Surg 1987;122:1375-9.
10. Kokal WA, Gardine RL, Sheibani K, Morris PL, Prager E, Zak IW, et al. Tumor DNA content in resectable, primary colorectal carcinoma. Ann Surg 1989;209:188-93.
11. Kouri M, Pyrhönen S, Mecklin J-P, Järvinen H, Laasonen A, Franssila K, et al. The prognostic value of DNA-ploidy in colorectal carcinoma: a prospective study. Br J Cancer 1990;62:976-81.
12. Rognum TO, Lund E, Meling GI, Langmark F. Near diploid large bowel carcinomas have better five-year survival than aneuploid ones. Cancer 1991;68:1077-81.
13. Witzig TE, Loprinzi CL, Gonchoroff NJ, Reiman HM, Cha SS, Wieand HS, et al. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 1991;68:879-88.
14. Tsuchiya A, Ando Y, Ishii Y, Yoshida T, Abe R. Flow cytometric DNA analysis in Japanese colorectal cancer. A multivariate analysis. Eur J Surg Oncol 1992;18:585-90.
15. Fisher ER, Siderits RH, Sass R, Fisher B. Value of assessment of ploidy in rectal cancers. Arch Pathol Lab Med 1989;113:525-8.
16. Visscher DW, Zarbo RJ, Ma CK, Sakr WA, Crissman JD. Flow cytometric DNA and clinicopathologic analysis of Dukes' A & B colonic adenocarcinomas: a retrospective study. Mod Pathol 1990;3:709-12.
17. Enker WE, Kimmel M, Cibas ES, Cranor ML, Melamed MR. DNA/RNA content and proliferative fractions of colorectal carcinomas: a five-year prospective study relating flow cytometry to survival. J Natl Cancer Inst 1991;83:701-7.
18. Tang R, Ho Y-S, You YT, Hsu KC, Chen JS, Changchien CR, et al. Prognostic evaluation of DNA flow cytometric and histopathologic parameters of colorectal cancer. Cancer 1995;76:1724-30.
19. Bauer KD, Bagwell CB, Giaretti W, Melamed M, Zarbo RJ, Witzig TE, et al. Consensus review of the clinical utility of DNA flow cytometry in colorectal cancer. Cytometry 1993;14:486-91.
20. Lanza G Jr., Maestri I, Ballotta MR, Dubini A, Cavazzini L. Relationship of nuclear DNA content to clinicopathologic features in colorectal cancer. Mod Pathol 1994;7:161-5.
21. Lanza G Jr., Maestri I, Dubini A, Gafà R, Santini A, Ferretti S, et al. p53 expression in colorectal cancer: relation to tumor type, DNA ploidy pattern, and short-term survival. Am J Clin Pathol 1996;105:604-12.
22. Hermanek P, Sobin LH, editors. UICC TNM Classification of malignant tumours. 4th edition. Berlin: Springer-Verlag, 1987:47-9.
23. Jass JR, Sobin LH. Histological typing of intestinal tumours. In: World Health Organization. International histological classification of tumours. 2nd edition. Berlin: Springer-Verlag, 1989:32-3.
24. Jass JR, Atkin WS, Cuzick J, Bussey HJR, Morson BC, Northover JMA, et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology 1986;10:437-59.
25. Lanza G Jr., Cavazzini L, Borghi L, Ferretti S, Buccoliero F, Rubbini M. Immunohistochemical assessment of growth fractions in colorectal adenocarcinomas with monoclonal antibody Ki-67. Relation to clinical and pathological variables. Pathol Res Pract 1990;186:608-18.
26. Hiddemann W, Schumann J, Andreef M, Barlogie B, Herman CJ, Leif RC, et al. Convention on nomenclature for DNA cytometry. Cancer Genet Cytogenet 1984;13:181-3.
27. Wirsching RP, Lamerz R, Wiebecke B, Demmel N, Liewald F, Valet G. Flow cytometric evaluation of colorectal carcinoma as completion of conventional tumor examination. J Exp Clin Cancer Res 1987;6:117-28.
28. Silvestrini R, D'Agnano I, Faranda A, Costa A, Zupi G, Cosimelli M, et al. Flow cytometric analysis of ploidy in colorectal cancer: a multicentric experience. Br J Cancer 1993;67:1042-6.
29. Sciallero S, Bonelli L, Geido E, Lettieri L, Zeraschi E, Bruzzi P, et al. Lack of prognostic value of flow cytometric DNA content analysis in colorectal adenocarcinomas. Eur J Cancer 1994;30A:569.
30. Delattre O, Olschwang S, Law DJ, Melot T, Remvikos Y, Salmon RJ, et al. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989;ii:353-6.
31. Offerhaus GJA, De Feyter EP, Cornelisse CJ, Tersmette KWF, Floyd J, Kern SE, et al. The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology 1992;102:1612-9.
32. Meling GI, Lothe RA, Borresen A-L, Graue C, Hauge S, Clausen OPF, et al. The TP53 tumour suppressor gene in colorectal carcinomas. II. Relation to DNA ploidy pattern and clinicopathological variables. Br J Cancer 1993;67:93-8.
33. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990;113:779-88.
34. Pocard M, Salmon RJ, Muleris M, Remvikos Y, Bara J, Dutrillaux B, et al. Deux côlons - deux cancers? Adénocarcinomes coliques proximal ou distal: arguments en faveur d'une cancérogenèse distincte. Bull Cancer (Paris) 1995;82:10-21.
35. Kern SE, Fearon ER, Tersmette KWF, Enterline JP, Leppert M, Nakamura Y, et al. Allelic loss in colorectal carcinoma. JAMA 1989;261:3099-103.
36. Jen J, Kim H, Piantadosi S, Liu Z-F, Levitt RC, Sistonen P, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331:213-21.
37. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-8.
38. Lothe RA, Peltomäki P, Meling GI, Aaltonen LA, Nyström-Lahti M, Pylkkänen L, et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993;53:5849-52.
39. Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994;145:148-56.
40. Goh H-S, Chan C-S, Rhine K, Smith DR. p53 and behaviour of colorectal cancer. Lancet 1994;344:233-4.
41. Campo E, Miquel R, Jares P, Bosch F, Juan M, Leone A, et al. Prognostic significance of the loss of heterozygosity of Nm23-H1 and p53 genes in human colorectal carcinomas. Cancer 1994;73:2913-21.
42. Bocker T, Schlegel J, Kullmann F, Stumm G, Zirngibl H, Epplen JT, et al. Genomic instability in colorectal carcinomas: comparison of different evaluation methods and their biological significance. J Pathol 1996;179:15-9.
43. Laurent-Puig P, Olschwang S, Delattre O, Remvikos Y, Asselain B, Melot T, et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992;102:1136-41.
44. O'Connell MJ, Schaid DJ, Ganju V, Cunningham J, Kovach JS, Thibodeau SN. Current status of adjuvant chemotherapy for colorectal cancer: can molecular markers play a role in predicting prognosis? Cancer 1992;70:1732-9.
45. Goh H-S, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995;55:5217-21.
46. Giaretti W, Santi L. Tumor progression by DNA flow cytometry in human colorectal cancer. Int J Cancer 1990;45:597-603.
47. Bauer KD, Lincoln ST, Vera-Roman JM, Wallemark CB, Chmiel JS, Madurski ML, et al. Prognostic implications of proliferative activity and DNA aneuploidy in colonic adenocarcinomas. Lab Invest 1987;57:329-35.
48. Giaretti W, Danova M, Geido E, Mazzini G, Sciallero S, Aste H, et al. Flow cytometric DNA index in the prognosis of colorectal cancer. Cancer 1991;67:1921-7.
49. Harlow SP, Eriksen BL, Poggensee L, Chmiel JS, Scarpelli DG, Murad T, et al. Prognostic implications of proliferative activity and DNA aneuploidy in Astler-Coller Dukes stage C colonic adenocarcinomas. Cancer Res 1991; 51:2403-9.
50. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-6.
51. Shulman K, Schilsky R. Adjuvant therapy of colon cancer. Semin Oncol 1995;22:600-10.
52. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995;13:2936-43.